✨ 6 results found - Searched 22785 records in 4ms.
Tesis
Analisis Potensi Interaksi Obat Pada Tatalaksana Kanker Paru Karsinoma Bukan Sel Kecil (KPKBSK) Stage Lanjut di RS Kanker Dharmais Tahun 2023
2024 | BY Anggi Gayatri - Purwantyastuti Ascobat - Noorwati Soetandyo - Yolanda Safitri- Analysis of Potential Drug Interactions in the Management of Non-Small Cell Carcinoma Lung Cancer (NSCLC) Advanced Stage at Dharmais Cancer Hospital in 2023.
- Nomor Panggil T24404fk
Disertasi
Peran MiR-10b, MiR-21, SuPAR dan PAI-1 Sebagai Prediktor Respons Terapi dan Progresivitas pada Kanker Paru Jenis Karsinoma Bukan Sel Kecil (KPKBSK).
2017 | BY Lyana Setiawan - Noorwati Sutandyo - Siti Boedina Kresno - Rahajuningsih Setiabudy- The Role of MiR-10b, MiR-21, Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), and Plasminogen Activator Inhibitor (PAI)-1 as Predictors of Treatment Response and Progressivity in Non-Small Cell Lung Cancer (NSCLC).
- Nomor Panggil D17020fk
Tesis
Masa tahan Hidup Pasien Kanker Paru Jenis Karsinoma Jenis Sel Kecil yang Mendapat Monoterapi Dosetaksel sebagai Kemoterapi Lini Kedua dan Faktor Faktor yang Mempengaruhi
2014 | BY Fadlun Bukayer - Anwar Jusuf - Elisna Syahruddin- SURVIVAL RATE OF DOCETAXEL AS SECONDLINE CHEMOTHERAPY FOR NSCLC PATIENTS IN PERSAHABATAN HOSPITAL JAKARTA.
- Nomor Panggil T14334fk
Tesis
Hubungan kadar vascular endothelial growth factor (VEGF) cairan pleura pada kanker paru karsinoma bukan sel kecil terhadap respons terapi
2025 | BY Sita Laksmi Andarini - Jamal Zaini - Fitriani Muchtar- The Relationship between Pleural Fluid Vascular Endothelial Growth Factor (VEGF) levels in Non-Small Cell Lung Cancer and Response Therapy.
- Nomor Panggil T25362fk
Tesis
Proporsi gambaran penyakit paru interstisial pada pasien kanker paru karsinoma bukan sel kecil dengan terapi epidermal growth factor receptor tyrosine kinase inhibitor di RSUP Persahabatan
2023 | BY Marscha Iradyta Ais - Sita Laksmi Andarini - Dianiati Kusumo Sutoyo - Maryastuti- The proportion of interstial lung disease features in patients with non small cell lung cancer treated with epidermal growth factor receptors tyrosine kinase inhibitor at Persahabatan Hospital.
- Nomor Panggil T23187fk
Tesis
Efikasi dan Toksisiti Erlotinib/Gefitinib sebagai Terapi Lini Kedua Pada Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil
2015 | BY Sita Laksmi Andarini - Jamaluddin M. - Achmad Hudoyo- Efficacy and Toxicity Erlotinib/Gefitinib as Second Line Therapy in Non-Small Cell Lung Cancer Patients.
- Nomor Panggil T 15 543 FK